Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Xigris Sepsis Benefit Defended By FDA In NEJM 

Executive Summary

An FDA analysis of Xigris PROWESS trial data suggests that Lilly's tightening of patient exclusion criteria during the study does not account for greater drug benefit seen after the protocol change
Advertisement

Related Content

Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says
Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA
Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients
Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients
Advertisement
UsernamePublicRestriction

Register

PS040548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel